Eli Lilly and Company
Tracked across 88 events · 2453 articles · First seen Mar 09, 2018 · Last active Aug 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Eli Lilly and Company has launched its cancer drug Tanstrive in India, expanding its market presence and offering a new treatment option for patients with RET-altered cancers. This launch is expected to positively impact the company's revenue and reputation in the Indian market.
Jun 25, 2026 · 7 articles
Business
Impact: Eli Lilly and Company obtained exclusive worldwide rights (excluding Korea) to develop, manufacture, and commercialize sonefpeglutide, expanding its pipeline in areas like short bowel syndrome and other indications, potentially leading to new revenue streams.
Jun 01, 2026 · 11 articles
Business
Impact: Eli Lilly and Company is acquiring three vaccine developers, marking its re-entry into the infectious disease space and expanding its R&D efforts. This move is expected to support its growth beyond its core diabetes and obesity portfolio.
May 26, 2026 · 7 articles
Business
Impact: Eli Lilly is the acquirer, paying $2.8B upfront for Atai Life Sciences to bolster its neuroscience pipeline and diversify beyond its weight-loss drug franchise. The deal is part of a broader acquisition spree funded by strong commercial performance.
Jul 16, 2026 · 25 articles
Tech
A new US study published in The BMJ found that Tirzepatide (tirzepatide), a GLP-1 receptor agonist used to treat type 2 diabetes and obesity, significantly reduces the risk of heart attacks in patients with type…
Impact: Manufacturer of Tirzepatide; reported strong sales growth and benefits from positive study results.
Aug 05, 2026 · 13 articles
Regulatory
Eli Lilly and Company filed six lawsuits against U.S. companies accused of illegally selling black-market versions of its experimental obesity drug retatrutide. The defendants include compounding pharmacies, medical spas, and online sellers: Aesthetic Envy Cosmetic…
Impact: Eli Lilly is the plaintiff, filing six lawsuits and escalating its campaign against unauthorized sellers of retatrutide. The company also delayed its FDA submission to Q1 2027 and allowed limited early access, reflecting both legal and regulatory actions that protect its pipeline and market position.
Aug 12, 2026 · 6 articles
Business
Impact: Main rival; maintains lead with Tirzepatide and Tirzepatide, but faces lawsuit and competition from oral Semaglutide.
Aug 03, 2026 · 6 articles
Regulatory
Impact: Eli Lilly and Company agreed to lower prices for its obesity drug Zepbound and will sell a starter dose for $299 a month, with additional doses up to $449, representing $50 reductions from current direct-to-patient prices. Its sales of Zepbound have tripled this year to over $9 billion.
Nov 06, 2025 · 6 articles
Tech
Impact: Eli Lilly and Company produces donanemab (Kisunla), one of the anti-amyloid drugs whose effectiveness was questioned by the Cochrane review, potentially impacting its sales and stock price.
Apr 16, 2026 · 6 articles
Business
Impact: Eli Lilly and Company is a leading pharmaceutical company with strong balance sheets, enabling it to be a major acquirer in the current M&A wave. It is also facing patent expirations on some of its blockbuster drugs.
May 01, 2026 · 6 articles
Business
Impact: Eli Lilly and Company has partnered with DKSH to expand the distribution and promotion of its pharmaceutical products in China — Hong Kong and China — Macau, ensuring continued patient access to its medicines.
Jul 06, 2026 · 6 articles
Tech
Impact: As the parent company of Verve PCSK9-inhibitor gene therapy>>>, Eli Lilly and Company>>> is a key developer of VERVE-102, a gene-editing therapy that has shown promising results in lowering cholesterol. This breakthrough could significantly impact its future market position in cardiovascular medicine.
May 26, 2026 · 12 articles
Business
Impact: Eli Lilly and Company expanded its exclusive global rights to Camurus' Fluid Crystal technology, allowing it to develop and commercialize long-acting cardiometabolic drugs for an additional compound class, which could lead to new revenue streams.
Jun 01, 2026 · 10 articles
Tech
Impact: Eli Lilly and Company>>> produces GLP-1 drugs like Zepbound, Mounjaro, and Trulicity, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
Regulatory
Impact: Eli Lilly and Company is a pharmaceutical company also facing lawsuits for its GLP-1 medications, Tirzepatide and Tirzepatide, which are alleged to have caused NAION. The company is accused of failing to warn consumers about these risks.
May 22, 2026 · 7 articles
Business
Impact: Eli Lilly and Company is a major competitor to Novo Nordisk in the weight-loss and diabetes drug market, with its drug Zepbound gaining market share against Novo Nordisk's Wegovy.
Sep 10, 2025 · 6 articles
Business
Impact: Eli Lilly and Company's drug Tirzepatide has been a strong competitor to Semaglutide in India, prompting Novo Nordisk to cut prices. Eli Lilly and Company has gained significant market share.
Nov 11, 2025 · 6 articles
Business
Impact: Eli Lilly and Company faces increased competition with Novo Nordisk's Wegovy pill launch, potentially impacting its market dominance in weight-loss drugs. Its shares fell following the announcement.
Jan 05, 2026 · 7 articles
Tech
Impact: Eli Lilly and Company produces Tirzepatide and Tirzepatide, which are GLP-1 agonist drugs. The study's findings on rapid weight regain after stopping medication could affect the perceived long-term efficacy and market demand for their products.
Jan 08, 2026 · 6 articles
Tech
Impact: Eli Lilly and Company collaborated on a new study that found a 71% higher risk of cardiovascular events or death in people with obstructive sleep apnea, especially those with obesity. This research could influence the development of new treatments and diagnostics, potentially benefiting Eli Lilly and Company's market position in related therapeutic areas.
Apr 03, 2026 · 6 articles
Domestic
Impact: Eli Lilly and Company's drug, Tirzepatide, is also included in France's reimbursement plan, which will expand its market reach within the European Union.
May 28, 2026 · 6 articles
Business
Nxera Pharma reported its consolidated results for the second quarter ended 30 June 2026, showing a significant improvement in financial performance. Revenue increased to JPY 18,910 million (US$119.6 million), up from JPY 15,095 million in…
Impact: Eli Lilly completed its acquisition of KC Pharmaceuticals, strengthening its sleep disorder portfolio. Nxera retains rights to future milestone and royalty payments from the orexin programs, benefiting Lilly's pipeline.
Aug 07, 2026 · 6 articles
Domestic
Impact: Eli Lilly and Company rose after the United States — Food and Drug Administration approved its new weight loss pill, Foundayo.
Apr 01, 2026 · 14 articles
Business
Impact: Eli Lilly and Company supports the Eli Lilly and Company, which committed approximately $5 million to Partners In Health. This contributes to its philanthropic efforts in global health.
Jun 09, 2026 · 6 articles
Regulatory
Impact: Eli Lilly's Zepbound is another GLP-1 drug involved; the study could prompt regulatory actions that impact its distribution.
Jul 07, 2026 · 6 articles
Business
OPKO Health, Inc. announced on August 13, 2026, the expansion of its financing relationship with Healthcare Royalty (HCRx), a business of KKR, through the issuance of an additional $125 million aggregate principal amount of senior…
Impact: Eli Lilly is the licensor of mazdutide to OPKO, and the royalties from this license secure the notes. The deal highlights the commercial potential of mazdutide in China.
Aug 13, 2026 · 6 articles
Business
Impact: Eli Lilly and Company>>> advanced after positive trial results for its next-generation obesity drug, retatrutide, which showed benefits beyond weight loss.
May 20, 2026 · 72 articles
Tech
Impact: Manufacturer of tirzepatide (Mounjaro, Zepbound); similar impact as Novo Nordisk.
Jul 14, 2026 · 6 articles
Business
Impact: Eli Lilly manufactures Mounjaro and Zepbound, GLP-1 drugs included in the study. The findings could enhance the perceived economic value of its products.
Jul 21, 2026 · 6 articles
Tech
Impact: Manufacturer of tirzepatide (Mounjaro, Zepbound); similar potential negative impact on product perception due to hair loss association.
Jul 22, 2026 · 6 articles
+ 58 more events
View on Dashboard
90
Eli Lilly and Company filed lawsuits Aesthetic Envy Cosmetic CentersLilly sues six over...
90
Eli Lilly and Company filed lawsuits Astra LLCLilly sues six over...
90
Eli Lilly and Company filed lawsuits Legendary PeptidesLilly sues six over...
90
Eli Lilly and Company filed lawsuits Striker PharmacyLilly sues six over...
90
Eli Lilly and Company filed lawsuits Texas PeptidesLilly sues six over...
90
Eli Lilly and Company filed lawsuits Lone Star Peptide CoLilly sues six over...
85
Eli Lilly and Company produced drugsMounjaro reduces heart attack risk
80
Eli Lilly and Company delayed FDA submission United States — Food and Drug AdministrationLilly sues six over...
80
Nxera Pharma achieved milestones Eli Lilly and CompanyNxera Pharma Q2 2026 Results
70
Eli Lilly and Company agreed to lower pricesBank of America GLP-1...
70
Eli Lilly and Company participated in financing Remedium BioLifespan Vision Leads...
70
Eli Lilly and Company referred to regulators United States — Food and Drug AdministrationLilly sues six over...
70
Eli Lilly and Company referred to regulators United States — United States Department of JusticeLilly sues six over...
60
Eli Lilly and Company raised forecastIran-Oman Strait of Hormuz...
60
Eli Lilly and Company reported listingsLilly sues six over...
60
Eli Lilly and Company allowed early accessLilly sues six over...
50
Eli Lilly and Company called for actionLilly sues six over...
50
Eli Lilly and Company manufactured exenatideGLP-1 drugs show promise for PMOS
+ 98 more relationships
View on Dashboard
ERGEN INTELLIGENCE
Track Eli Lilly and Company live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard